We are live on ! Find out more
DTC

Deep Track Capital Portfolio holdings

AUM $6.87B
1-Year Est. Return 205.24%
This Fund
S&P 500
This Quarter Est. Return
-2.69%
1 Year Est. Return
+205.24%
3 Year Est. Return
+440.18%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.09B
AUM Growth
+$407M
Cap. Flow
+$944M
Cap. Flow %
30.56%
Top 10 Hldgs %
53.08%
Holding
79
New
16
Increased
25
Reduced
8
Closed
10

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$94.7M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$86.1M
3
PTGX icon
Protagonist Therapeutics
PTGX
+$83.8M
4
GERN icon
Geron
GERN
+$83.2M
5
TARS icon
Tarsus Pharmaceuticals
TARS
+$73.4M

Top Sells

Rank Stock Value
1
SWTX
SpringWorks Therapeutics
SWTX
+$125M
2
HRMY icon
Harmony Biosciences
HRMY
+$49.9M
3
NMRA icon
Neumora Therapeutics
NMRA
+$42.4M
4
GH icon
Guardant Health
GH
+$42.1M
5
GMAB icon
Genmab
GMAB
+$41.7M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NMRA icon
76
Neumora Therapeutics
NMRA
$150M
– –
-4,000,000
Closed -$42.4M
FLNA
77
PUT
Filana Therapeutics
FLNA
$32.6M
– –
-500,000
Closed -$1.18M
SWTX
78
DELISTED
SpringWorks Therapeutics
SWTX
– –
-3,460,756
Closed -$125M
VRNA
79
DELISTED
Verona Pharma
VRNA
– –
-850,000
Closed -$39.5M
1 2 3
4

Similar funds

PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
EWM
Empirical Wealth Management Seattle, Washington $6.85B AUM 30.02% 1-Year Est. Return
NP
NorthRock Partners Minneapolis, Minnesota $6.89B AUM 19.83% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $6.92B AUM 24.7% 1-Year Est. Return
RCWMU
Rothschild & Co Wealth Management (UK) London, United Kingdom $6.93B AUM 1.4% 1-Year Est. Return
CA
Cambridge Associates Boston, Massachusetts $6.93B AUM 17.96% 1-Year Est. Return
LIP
Liontrust Investment Partners London, United Kingdom $6.8B AUM 23.31% 1-Year Est. Return
CI
Cincinnati Insurance Fairfield, Ohio $6.94B AUM 20.24% 1-Year Est. Return

Deep Track Capital's Q1 2025 Portfolio in Review

As of Q1 2025, Deep Track Capital held 79 positions worth $3.09B, up 15% from $2.68B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Deep Track Capital deployed $944M of net new capital in Q1 2025, opening 16 new positions and adding to 25 existing holdings. Its largest new stake was Sarepta Therapeutics: 899,731 shares worth $57.4M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier.

On the sell side, the largest reduction was Guardant Health, an estimated $42.1M trimmed.

  • Deep Track Capital's largest Q1 2025 buy was Sarepta Therapeutics: 899,731 shares worth $57.4M.
  • Deep Track Capital added most to Ionis Pharmaceuticals in Q1 2025, an estimated $86.1M increase.
  • Deep Track Capital's biggest Q1 2025 reduction was Guardant Health, cutting an estimated $42.1M.
  • Deep Track Capital fully exited SpringWorks Therapeutics in Q1 2025, selling an estimated $125M.
  • Deep Track Capital's ten largest holdings make up 53% of its $3.09B portfolio in Q1 2025.
  • Deep Track Capital opened 16 new positions and closed 10 in Q1 2025.
  • Deep Track Capital's portfolio value rose 15% quarter-over-quarter to $3.09B.

Based on Deep Track Capital's 13F filing for Q1 2025, filed 15 May 2025.